Profund Advisors LLC Buys 1,388 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Profund Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,913 shares of the biopharmaceutical company’s stock after acquiring an additional 1,388 shares during the quarter. Profund Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $6,779,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after acquiring an additional 121,545 shares during the period. Price T Rowe Associates Inc. MD increased its position in Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock worth $1,379,467,000 after purchasing an additional 89,579 shares during the last quarter. Amundi boosted its stake in Regeneron Pharmaceuticals by 3.4% during the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock worth $979,794,000 after buying an additional 52,166 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock worth $724,984,000 after buying an additional 174,056 shares during the period. Finally, American Century Companies Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 2.1% in the first quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company’s stock valued at $458,211,000 after purchasing an additional 14,921 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 1.6%

Shares of REGN stock opened at $657.53 on Monday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $834.42. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The firm has a market cap of $69.69 billion, a PE ratio of 15.75, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The stock has a 50 day moving average of $588.03 and a 200-day moving average of $567.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the previous year, the firm posted $12.46 earnings per share. The company’s revenue was up .9% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the company an “equal weight” rating in a report on Wednesday, October 29th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a “buy” rating and a $890.00 price objective on the stock. Sanford C. Bernstein increased their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Finally, Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $796.57.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. The trade was a 73.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 7.02% of the stock is currently owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.